AI Article Synopsis
Article Abstract
A human scFv, 15-9, was selected from a phage display library for binding to murine laminin-1. A diabody was made from the scFv by shortening the linker from 15 to 5 amino acids between the VH and VL sequence. Radioiodinated scFv and diabody were analyzed for size, binding to laminin, and biodistribution in tumor bearing mice. Diabody preparations at concentrations greater than 10 nM were largely dimer forms (approximately 60 kDa) as judged by gel filtration, but diluted diabody was eluted as a monomer (approximately 30 kDa). At low concentrations the radiolabeled diabody did not bind well to laminin. The (125)I diabody had significantly lower accumulation in tumors than did the scFv when injected at lower concentrations. These data indicate that the diabody dimer dissociates at concentrations of about 10nM resulting in monomers with no binding activity for laminin and poor tumor homing properties.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2004.12.114 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing aggregate reduction using anion exchange hybrid filter in an immunocytokine diabody fusion protein purification process.
J Chromatogr A
January 2025
Analytical Development, BDL, PDS&T, AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA; Previously Purification Development, BDL, PDS&T, AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA.
Significant aggregation challenges were encountered during the manufacturing processing of an immunocytokine diabody fusion protein. To mitigate this issue and reduce aggregates in the purification process, a variety of depth filters were evaluated for harvest clarification and post-Protein A intermediate filtration. Emphaze™ AEX Hybrid Purifier, a fully synthetic quaternary amine functionalized anion exchange (AEX) nonwoven filter, was found to be particularly effective in removing aggregates during both harvest clarification and post-Protein A intermediate filtration steps.
View Article and Find Full Text PDFStructural insight into rabies virus neutralization revealed by an engineered antibody scaffold.
Structure
December 2024
Institute of Biotechnology, Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland; Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland. Electronic address:
Host-cell entry of the highly pathogenic rabies virus (RABV) is mediated by glycoprotein (G) spikes, which also comprise the primary target for the humoral immune response. RABV glycoprotein (RABV-G) displays several antigenic sites that are targeted by neutralizing monoclonal antibodies (mAbs). In this study, we determined the epitope of a potently neutralizing human mAb, CR57, which we engineered into a diabody format to facilitate crystallization.
View Article and Find Full Text PDFA comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs.
MAbs
October 2024
Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, Swiss Federal Institute of Technology, Zurich, Switzerland.
Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs). However, the translation of these non-natural molecules into successful therapeutics can be hampered by developability challenges. Here, we systematically analyzed 64 different antibody constructs targeting Tumor Necrosis Factor (TNF) which cover 8 distinct molecular format families, encompassing full-length antibodies, various types of single chain variable fragments, and bispecifics.
View Article and Find Full Text PDFEfficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells.
Leukemia
December 2024
Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Article Synopsis
- CAR T-cell therapies targeting specific antigens have been approved for treating B- and plasma-cell cancers, but their efficacy is limited by low antigen expression and safety issues due to the lack of control over their activity.
- A new approach, called adaptor-CAR (AdFITC-CAR) T-cells, was developed to target a broader range of AML antigens and allow for modulation of T-cell activity, potentially avoiding damage to healthy cells.
- Experiments showed that AdFITC-CAR T-cells, especially when combined with multiple adaptor proteins, significantly improved the killing of AML cells and demonstrated effective therapy in mouse models, suggesting a promising advance in treating AML.
Synthesis and evaluation of anti-PD-L1-B11 antibody fragments for PET imaging of PD-L1 in breast cancer and melanoma tumor models.
Sci Rep
August 2024
Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN, 55905, USA.
There is a critical need to non-invasively assess the PD-L1 expression in tumors as a predictive biomarker for determining the efficacy of anti-PD-1/PD-L1 immunotherapies. Non-invasive imaging modality like positron emission tomography (PET) can be a powerful tool to assess the PD-L1 expression in the whole body including multiple metastases as a patient selection criterion for the anti-PD-1/PD-L1 immunotherapy. In this study, we synthesized B11-nanobody, B11-scFv and B11-diabody fragments from the full-length anti-PD-L1 B11 IgG.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!